ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 360

Initial Introduction of Treat-to-Target Strategy in Patients with Recent Onset Rheumatoid Arthritis Is More Effective Than Delayed Introduction of Strategy with More Clinical and Functional Remission Achieved for 2-Years: Results of the Treating to Twine Targets (T-4) Study

Yukitomo Urata1, Yoshihide Nakamura2 and Ken-ichi Furukawa3, 1Rheumatology, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, 2Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, 3Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: clinical trials, functional status, remission and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose:

To compare the clinical, radiological and functional efficacy of initial versus delayed introduction of strategy which is treat-to-target to patients with recent onset rheumatoid arthritis (RA) after 2-years follow up.

Methods:

A post hoc analysis of the T-4 (treating to twine targets) study which is a multicenter, randomized and open trial in newly diagnosed RA patients (mean duration 1.4±1.1 yrs) who has not previously received disease-modifying anti-rheumatic drugs (DMARDs) was performed. In the T-4 study, a total of 243 RA patients were randomly allocated to one of four strategy groups: routine care (R group, n=62); disease activity score in 28 joints (DAS28)-driven therapy (D group, n=60); matrix metalloproteinase (MMP)-3-driven therapy (M group, n=60); or both DAS28- and MMP-3-driven therapy group (Twin; T group, n=61). Specifically, medication was started with sulfasalazine (1 g/day) in all intervention groups. Targets were DAS28 <2.6 for D group, MMP-3 normalisation for M group, and both DAS28 <2.6 and MMP-3 normalisation for T group. If the value in question did not fall below the previously measured level, we intensified medication including methotrexate, other DMARDs and biologic agents. From 56 weeks all patients were allocated to T group, treatment was adjusted every three months if the value in question did not fall below the previously measured level. 61patinets in initial treat-to-target introduced group (T→Tgroup) were compared with 62 patients in delayed treat-to-target introduced group (R→Tgroup) for 2 years. Functional ability was measured by the Health Assessment Questionnaire (HAQ), radiological progression was measured by Sharp/van der Heijde scoring (SHS).

Results: Baseline differences between the two groups were not significant. Clinical (simplified disease activity index≤3.3) and functional (HAQ=0) remission at 2 years was achieved by more patients in initial treat-to-target introduced group (T→Tgroup) (51% and 74%) than in delayed group (R→T group) (18%; p<0.0001 and 50%; p=0.0063). There are no significant difference between initial and delayed group (52% versus 47%; p=0.5283) for radiographic remission (DSHS<0.5).

Conclusion:

The results of post hoc analysis in T-4 study suggest that initial introduction of treat-to-target strategy in patients with recent onset RA is more effective than delayed introduction of strategy with more clinical and functional remission achieved for 2-years.


Disclosure:

Y. Urata,
None;

Y. Nakamura,
None;

K. I. Furukawa,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/initial-introduction-of-treat-to-target-strategy-in-patients-with-recent-onset-rheumatoid-arthritis-is-more-effective-than-delayed-introduction-of-strategy-with-more-clinical-and-functional-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology